Professor Gareth H Williams is co-founder and Medical Director at Oncologica
Professor Williams is the medical lead for Oncologica®. He is responsible for directing business strategy, overseeing technical operations and directing all medical aspects of the molecular diagnostic and contract research services. Professor Williams also co-directs the Research and development arm of Oncologica®.
Professor Williams is an internationally recognised molecular diagnostic pathologist who, as the Sir John Bland Sutton Chair of Pathology, headed the Department of Pathology at University College London/University College London Hospitals (UCL/UCLH) from 2002-2014 before taking up the post of Medical Director at Oncologica®. He has previously held prestigious clinical academic posts at leading medical institutions both in the UK and US including Cambridge University, Harvard University and University College London.
His medical research focuses on translating basic discoveries in the cancer cell cycle field into diagnostic and therapeutic applications. This translational pipeline of research has generated high impact academic papers and international patent filings. A number of these discoveries have been commercialised by Biopharma into a range of diagnostic tests and therapeutic targeted agents.
Published Research Papers
Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma
Published: March 25, 2022 DOI: https://doi.org/10.1371/journal.pone.0245817
Gareth H Williams, Alexander Llewelyn, Robert Thatcher, Keeda-Marie Hardisty, Marco Loddo
SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom
EClinical Medicine by the Lancet Published:July 14, 2021 DOI: https://doi.org/10.1016/j.eclinm.2021.101021
Gareth H Williams, Alexander Llewelyn, Ruben Brandao, Kaiya Chowdhary,Keeda-Marie Hardisty, Marco Loddo (2021)
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
Front Oncol. 2021; 11: 686776. Published online 2021 Jun 28. doi: https://doi.org/10.3389/fonc.2021.686776
Alfredo Molteni, Alice Bruson, Carla Strina, Carlo Azzini, Daniele Generali, Davide Cerra, Elena Marasco, Elisa Zago, Fabiola Giudici, Francesco Schettini, Gareth H Williams, Giovanni Scambia, Giuseppina Barbieri, Giuseppina Ferrero, Ida Paris, Luciano Xumerle, Manuela Milani, Marco Loddo, Marco Ungari, Maria Chiara Lazzari, Maria Rosa Cappelletti, Marianna Sirico, Nicoletta Ziglioli, Ottavia Bernocchi, Sergio Aguggini, Silvia Paola Corona, Valeria Cervoni
The actionable genomic mutational landscape in solid tumours
J Clin Oncol 38: 2020 (suppl; abstr e13642) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13642
Loddo M, Hardisty KM, Thatcher RP, Haddow TE, Williams GH (2020)
Immunofocus-PD-L1 high throughput quantitative next generation sequencing assay
J Clin Oncol 38: 2020 (suppl; abstr e13521) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13521
Williams GH, Thatcher RP, Haddow TE, Hardisty KM, Loddo M (2020)
Druggable fusion gene landscape in solid tumors
J Clin Oncol 38: 2020 (suppl; abstr e13517) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13517
Williams GH, Thatcher RP, Nevado B, Haddow TE, Hardisty KM, Loddo M (2020)